Tempest Therapeutics disclosed an exclusive option to license Hebei Senlang's CD7-targeted lentiviral vector platform and its in vivo CAR-T pipeline, including a BCMA/GPRC5D dual-targeting candidate in Phase 1 for multiple myeloma. The pre-market rally implies investor optimism for potential licensing deals, but terms and funding remain unclear. The outcome will hinge on the progression of deal terms and any accompanying financing.
TPST shares rose 23% on news of Roche collaboration. Tempest is advancing amezalpat into a pivotal Phase 3 liver cancer trial. Roche will supply atezolizumab, enhancing treatment options for HCC. Positive Phase 2 results showed significant survival improvements. Phase 3 study is expected to begin in Q1 2025.
